A decade on from the U.S. Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics, Inc., Professor Jacob Sherkow argues that what seemed like a political and cultural phenomenon has had a much narrower impact. Writing as the first author in a new paper published in Annual Review of Genomics and Human Genetics, Sherkow explains how the Myriad decision has had a modest impact on patents, largely hidden by other developments in science and law since the case was decided.